Valbenazine Tosylate Drug Asset Due Diligence Report 2026

This Valbenazine Tosylate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Valbenazine Tosylate can convert its Small molecule drug profile and VMAT2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Valbenazine Tosylate (query alias: valbenazine)
Modality / target	Small molecule drug; VMAT2; VMAT2 inhibitors
Highest global status	Approved
Originator	Neurocrine Biosciences, Inc.
Active developers	Neurocrine Biosciences, Inc., Tanabe Pharma Corp., Janssen Pharmaceuticals, Inc.

The MCP disease footprint includes Huntington Disease, Tardive Dyskinesia, Chorea. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07105111	Phase 4	Recruiting	50	Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score (AIMS 1-7) at Week 24
NCT06107829	Phase 4	Withdrawn	Not disclosed	Change in AIMS total scores of items 1-7
NCT06312189	Phase 3	Enrolling by invitation	7	Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia

Phase 4; n=59; evaluation: not stated. Reported fields: Change From Baseline in the Tardive Dyskinesia Impact Scale (TDIS) Total Score at Week 24(Mean) = -8.0 score on a scale (95% Confidence Interval, -10.48 to -5.44); -; -

Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR

Not Applicable; n=8; evaluation: Positive. Reported fields: VMAT2 target occupancy = 54 % ; VMAT2 target occupancy = 92 % ; VMAT2 target occupancy = 70 %

Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy

Phase 3; n=not disclosed; evaluation: Negative. Reported fields: improvement in chorea = did not meet Not Met; improvement in chorea = did not meet Not Met

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Valbenazine Tosylate addresses Huntington Disease, Tardive Dyskinesia, Chorea. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2015-04-01	Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets	Phase 3	US$30.0M upfront; US$85.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Application of valbenazine, active metabolite of valbenazine or medicinal salt of valbenazine in preparation of megakaryocyte or platelet”. The milestone feed surfaced a patent-application signal described as “Liquid compositions of valbenazine for oral administration”. The milestone feed surfaced a patent-application signal described as “An improved process for the preparation of valbenazine tosylate”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO